XML 51 R41.htm IDEA: XBRL DOCUMENT v3.22.2.2
Collaborative Arrangements and Licensing Agreements, Roche (Details)
$ in Thousands
3 Months Ended 9 Months Ended
Sep. 30, 2022
USD ($)
Indication
Agreement
Jun. 30, 2022
USD ($)
Sep. 30, 2021
USD ($)
Sep. 30, 2022
USD ($)
Indication
Agreement
Sep. 30, 2021
USD ($)
Dec. 31, 2021
USD ($)
Collaborative Arrangement and Licensing Agreement [Abstract]            
Revenue $ 159,767   $ 133,093 $ 435,478 $ 370,450  
R&D Revenue [Member]            
Collaborative Arrangement and Licensing Agreement [Abstract]            
Revenue $ 87,357   $ 48,273 $ 212,599 $ 115,321  
Roche Collaborations [Member]            
Collaborative Arrangement and Licensing Agreement [Abstract]            
Number of collaboration agreements | Agreement 2     2    
Cumulative payments received $ 283,000     $ 283,000    
Deferred revenue $ 23,600     $ 23,600   $ 31,600
Roche Collaborations [Member] | Revenue [Member] | Strategic Partner [Member]            
Collaborative Arrangement and Licensing Agreement [Abstract]            
Concentration percentage 26.00%   3.00% 15.00% 3.00%  
Roche Collaborations [Member] | R&D Revenue [Member]            
Collaborative Arrangement and Licensing Agreement [Abstract]            
Revenue $ 41,500   $ 3,900 $ 65,400 $ 11,400  
Collaboration to Develop IONIS-FB-L with Roche [Member]            
Collaborative Arrangement and Licensing Agreement [Abstract]            
Number of collaboration agreements | Agreement 1     1    
Number of disease indications | Indication 2     2    
Maximum amount of payments receivable for development milestones $ 145,000     $ 145,000    
Maximum amount of payments receivable for regulatory milestones 279,000     279,000    
Maximum amount of payments receivable for sales-related milestones 280,000     $ 280,000    
Revenue 35,000 $ 13,800        
Collaboration to Develop IONIS-FB-L with Roche [Member] | Maximum [Member]            
Collaborative Arrangement and Licensing Agreement [Abstract]            
Royalty percentage received on net sales of medicine       20.00%    
Next prospective milestone $ 90,000     $ 90,000    
Collaboration to Develop IONIS-FB-L with Roche [Member] | GA [Member]            
Collaborative Arrangement and Licensing Agreement [Abstract]            
Number of disease indications | Indication 1     1    
Collaboration to Develop IONIS-FB-L with Roche [Member] | IgAN [Member]            
Collaborative Arrangement and Licensing Agreement [Abstract]            
Number of disease indications | Indication 1     1    
Collaboration to Develop Treatments for Huntington's Disease with Roche [Member]            
Collaborative Arrangement and Licensing Agreement [Abstract]            
Number of collaboration agreements | Agreement 1     1